Bio-Path Holdings (BPTH) Stock Heads for the Top on Patent News

Bio-Path BPTH Stock News

Bio-Path Holdings Inc (NASDAQ: BPTH) is making a run for the top in the market this morning, and for good reason. The company announced a Notice of Allowance from the United States Patent and Trademark Office. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

BPTH Stock Climbs on Patent News

In the press release, Bio-Path Holdings said tat it received a Notice of Allowance from the United States Patent and Trademark Office. The Notice surrounds claims related to the company’s lead product candidate, prexigebersen, in combination with either a cytidine analogue or the Bcr-Abl tyrosine kinase inhibitors dasatinib and nilotinib.

In the release, BPTH reminded investors that prexigebersen is a liposomal formulation containing the antisense oligodeoxynucleotide targeting growth factor receptor-bound protein 2 (Grb2).

The company went on to say that the new patent is titled, “Combination Therapy with Liposomal Antisense Oligonucleotides.” The patent will provide protection for application of prexigebersen in the treatment of a variety of cancers in combination with front-line therapies.

In a statement, Peter Nielsen, President and CEO at BPTH, had the following to offer:

This further strengthens our intellectual property portfolio and complements already granted patents. Our growing patent estate continues to be a valuable asset for Bio-Path as it provides protection not only for our core product portfolio and research efforts but now also offers broad protection in combination with established front-line therapies.

Bio-Path is currently in an ongoing Phase 2 clinical trial of prexigebersen in combination with decitabine as a treatment for acute myeloid leukemia (AML), and this new patent protects the unique therapy combination and supports our ongoing investment in this program to bring a new treatment option to patients with AML who have limited treatment options.

This Is Big News

The news released by Bio-Path this morning proved to be incredibly positive. The fact of the matter is that being successful in biotechnology takes more than an ability to come up with effective treatment options. Companies have to protect themselves.

Ultimately, the stronger the IP portfolio held by a biotechnology company, the stronger its ability to protect itself in the market when its candidates prove to be effective in the ailments that they were designed to treat. So, it’s not surprising to see that investors are excited this morning. All in all, BPTH stock is one to watch closely.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don't Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.